BridgeBio Pharma Inc. (BBIO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 31 |
Market Cap | 5.89B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.42 |
PE Ratio (ttm) | -12.88 |
Forward PE | n/a |
Analyst | Buy |
Ask | 31.58 |
Volume | 1,080,007 |
Avg. Volume (20D) | 2,537,226 |
Open | 31.57 |
Previous Close | 31.76 |
Day's Range | 31.02 - 32.11 |
52-Week Range | 21.62 - 41.04 |
Beta | undefined |
About BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...
Analyst Forecast
According to 12 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $46.5, which is an increase of 49.18% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News

2 months ago · seekingalpha.com
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With CaveatsBridgeBio Pharma, Inc.'s acoramidis is awaiting FDA's approval decision for transthyretin amyloidosis, with strong clinical data suggesting a likely approval and potential “blockbuster” status. The PD...